Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUDITH L WHITE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1316940018
CMS profile
14471
Location
KINGSPORT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$485.12

28 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $334.95 19
Food and Beverage $150.17 9

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $485.12 28

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUDITH L WHITE

NPI 1316940018 · CMS profile ID 14471

Allopathic & Osteopathic Physicians / Internal Medicine

KINGSPORT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1316940018?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

28 matching records · $485.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 28 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–28 of 28.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657925349 CMS
Eli Lilly and Company $2.0308/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657925351 CMS
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657925353 CMS
Eli Lilly and Company $10.2008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928825 CMS
Eli Lilly and Company $6.9508/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928827 CMS
Eli Lilly and Company $3.0608/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928829 CMS
Eli Lilly and Company $7.5108/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928831 CMS
Eli Lilly and Company $7.5208/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657928833 CMS
Eli Lilly and Company $17.0308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932257 CMS
Eli Lilly and Company $21.0008/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932259 CMS
Eli Lilly and Company $21.7608/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932261 CMS
Eli Lilly and Company $3.0608/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932263 CMS
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932265 CMS
Eli Lilly and Company $0.9808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932267 CMS
Eli Lilly and Company $2.0308/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657932269 CMS
Eli Lilly and Company $9.4508/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657935631 CMS
Eli Lilly and Company $9.1808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657942523 CMS
Eli Lilly and Company $10.2008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657942525 CMS
Eli Lilly and Company $51.0008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657945957 CMS
Eli Lilly and Company $15.3008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657945959 CMS
Eli Lilly and Company $51.0008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657945961 CMS
Eli Lilly and Company $84.0008/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949343 CMS
Eli Lilly and Company $4.4608/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949345 CMS
Eli Lilly and Company $128.0008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949347 CMS
Eli Lilly and Company $9.1808/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657949349 CMS
Eli Lilly and Company $4.0308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728304149 CMS
Eli Lilly and Company $2.0308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728304477 CMS
Eli Lilly and Company $1.2208/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728304479 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $485.12 28
PY2021 $2,163.83 6
PY2022 $51.76 3
PY2024 $1,672.68 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $640,741.74 27
PY2024 Principal investigator $267,189.88 19
PY2023 Recipient $98.80 1
PY2023 Principal investigator $96,720.88 105
PY2022 Recipient $85.00 1
PY2022 Principal investigator $1,700,193.53 16,257
PY2021 Recipient $242.50 1
PY2021 Principal investigator $910,699.42 50
PY2020 Recipient $1,336.87 14
PY2020 Principal investigator $850,450.68 67
PY2019 Principal investigator $1,175,554.95 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022 · part 1 of 4

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

5,000 records in this part · 16,258 in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,555.00 11/15/2022 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 889820779
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123503
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123505
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123507
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123509
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123511
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123513
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123515
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123517
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123519
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123521
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123523
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123525
Principal investigator 1 ModernaTX, Inc. $163.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123527
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130037
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130039
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130041
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130043
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130045
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130047
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130049
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130051
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130053
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130055
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130057
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130059
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130061
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130063
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130065
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130067
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130069
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130071
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130073
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130075
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130077
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130079
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130081
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130083
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130085
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130087
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130089
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130091
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130093
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130095
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130097
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130099
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130101
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130103
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130105
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130107
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130109
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130111
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130113
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130115
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130117
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130119
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130121
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130123
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130125
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130127
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130129
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130131
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130133
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130135
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130137
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130139
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130141
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130143
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130145
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130147
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130149
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130151
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130153
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130155
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130157
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130159
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130161
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130163
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130165
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130167
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130169
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130171
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130173
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130175
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130177
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130179
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130181
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130183
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130185
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130187
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130189
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130191
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130193
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130195
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130197
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130199
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130201
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130203
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130205
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130207
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130209
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130211
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130213
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130215
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130217
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130219
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130221
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130223
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130225
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130227
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130229
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130231
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130233
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130235
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130237
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130239
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130241
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130243
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130245
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130247
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130249
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130251
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130253
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130255
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130257
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130259
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130261
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130263
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130265
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130267
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130269
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130271
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130273
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130275
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130277
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130279
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130281
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130283
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130285
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130287
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130289
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130291
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130293
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130295
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130297
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130299
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130301
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130303
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130305
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130307
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130309
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130311
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130313
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130315
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130317
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130319
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130321
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130323
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130325
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130327
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130329
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130331
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130333
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130335
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130337
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130339
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130341
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130343
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130345
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130347
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130349
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130351
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130353
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130355
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130357
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130359
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130361
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130363
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130365
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130367
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130369
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130371
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130373
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130375
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130377
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130379
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130381
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130383
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130385
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130387
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130389
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130391
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130393
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130395
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130397
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130399
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130401
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130403
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130405
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130407
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130409
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130411
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130413
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130415
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130417
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130419
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130421
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130423
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130425
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130427
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130429
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130431
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130433
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130435
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130437
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130439
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130441
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130443
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130445
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130447
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130449
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130451
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130453
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130455
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130457
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130459
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130461
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130463
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130465
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130467
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130469
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130471
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130473
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130475
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130477
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130479
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130481
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130483
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130485
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130487
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130489
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130491
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130493
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130495
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130497
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130499
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130501
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130503
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130505
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130507
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130509
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130511
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130513
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130515
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130517
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130519
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130521
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130523
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130525
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130527
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130529
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130531
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130533
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130535
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130537
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130539
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130541
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130543
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130545
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130547
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130549
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130551
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130553
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130555
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130557
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130559
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130561
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130563
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130565
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130567
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130569
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130571
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130573
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130575
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130577
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130579
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130581
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130583
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130585
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130587
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130589
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130591
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130593
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130595
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130597
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130599
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130601
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130603
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130605
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130607
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130609
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130611
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130613
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130615
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130617
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130619
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130621
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130623
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130625
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130627
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130629
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130631
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130633
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130635
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130637
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130639
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130641
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130643
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130645
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130647
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130649
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130651
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130653
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130655
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130657
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130659
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130661
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130663
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130665
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130667
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130669
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130671
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130673
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130675
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130677
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130679
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130681
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130683
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130685
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130687
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130689
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130691
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130693
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130695
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130697
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130699
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130701
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130703
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130705
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130707
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130709
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130711
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130713
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130715
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130717
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130719
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130721
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130723
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130725
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130727
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130729
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130731
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130733
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130735
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130737
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130739
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130741
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130743
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130745
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130747
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130749
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130751
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130753
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130755
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130757
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130759
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130761
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130763
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130765
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130767
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130769
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130771
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130773
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130775
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130777
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130779
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130781
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130783
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130785
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130787
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130789
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130791
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130793
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130795
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130797
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130799
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130801
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130803
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130805
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130807
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130809
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130811
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130813
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130815
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130817
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130819
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130821
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130823
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130825
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130827
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130829
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130831
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130833
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130835
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130837
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130839
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130841
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130843
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130845
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130847
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130849
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130851
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130853
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130855
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130857
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130859
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130861
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130863
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130865
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130867
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130869
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130871
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130873
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130875
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130877
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130879
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130881
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130883
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130885
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130887
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130889
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130891
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130893
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130895
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130897
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130899
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130901
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130903
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130905
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130907
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130909
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130911
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130913
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130915
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130917
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130919
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130921
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130923
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130925
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130927
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130929
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130931
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130933
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130935
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130937
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130939
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963130941
Principal investigator 1 ModernaTX, Inc. $957.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131011
Principal investigator 1 ModernaTX, Inc. $957.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131013
Principal investigator 1 ModernaTX, Inc. $957.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131015
Principal investigator 1 ModernaTX, Inc. $957.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131017
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131049
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131051
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131175
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131177
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131179
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131181
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131183
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131185
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131187
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131189
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131191
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131193
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131215
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131217
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131295
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131297
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131299
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131301
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131303
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131305
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131319
Principal investigator 1 ModernaTX, Inc. $67.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963131397
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132211
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132213
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132215
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132217
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132219
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132221
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132223
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132225
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132227
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132229
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132231
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132233
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132235
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132237
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132239
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132241
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132243
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132245
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132247
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132249
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132251
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132253
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132255
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963132257
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133073
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133075
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133077
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133079
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133081
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133083
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133085
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133087
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133089
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133091
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133093
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133095
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133097
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133099
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133101
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133103
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133105
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133107
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133109
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133111
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133113
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133115
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133117
Principal investigator 1 ModernaTX, Inc. $706.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133119
Principal investigator 1 ModernaTX, Inc. $470.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133137
Principal investigator 1 ModernaTX, Inc. $470.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133139
Principal investigator 1 ModernaTX, Inc. $470.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133141
Principal investigator 1 ModernaTX, Inc. $470.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133143
Principal investigator 1 ModernaTX, Inc. $470.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133145
Principal investigator 1 ModernaTX, Inc. $470.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133147
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133163
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133165
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133167
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133169
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133171
Principal investigator 1 ModernaTX, Inc. $100.00 11/01/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963133173
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114653
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114655
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114657
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114659
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114661
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114663
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114665
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114667
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114669
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114671
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114673
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114675
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114677
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114679
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114681
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114683
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114685
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114687
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114689
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114691
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114693
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114695
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114697
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114699
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114701
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114703
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114705
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114707
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114709
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114711
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114713
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114715
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114717
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114719
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114721
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114723
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114725
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114727
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114729
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114731
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114733
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114735
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114737
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114739
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114741
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114743
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114745
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114747
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114749
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114751
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114753
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114755
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114757
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114759
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114761
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114763
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114765
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114767
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114769
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114771
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114773
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114775
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114777
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114779
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114781
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114783
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114785
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114787
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114789
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114791
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114793
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114795
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114797
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114799
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114801
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114803
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114805
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114807
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114809
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114811
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114813
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114815
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114817
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114819
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114821
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114823
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114825
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114827
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114829
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114831
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114833
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114835
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114837
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114839
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114841
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114843
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114845
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114847
Principal investigator 1 ModernaTX, Inc. $163.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963114849
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121281
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121283
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121285
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121287
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121289
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121291
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121293
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121295
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121297
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121299
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121301
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121303
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121305
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121307
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121309
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121311
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121313
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121315
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121317
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121319
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121321
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121323
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121325
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121327
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121329
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121331
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121333
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121335
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121337
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121339
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121341
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121343
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121345
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121347
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121349
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121351
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121353
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121355
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121357
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121359
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121361
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121363
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121365
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121367
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121369
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121371
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121373
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121375
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121377
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121379
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121381
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121383
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121385
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121387
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121389
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121391
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121393
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121395
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121397
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121399
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121401
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121403
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121405
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121407
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121409
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121411
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121413
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121415
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121417
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121419
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121421
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121423
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121425
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121427
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121429
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121431
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121433
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121435
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121437
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121439
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121441
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121443
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121445
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121447
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121449
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121451
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121453
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121455
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121457
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121459
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121461
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121463
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121465
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121467
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121469
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121471
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121473
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121475
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121477
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121479
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121481
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121483
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121485
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121487
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121489
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121491
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121493
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121495
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121497
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121499
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121501
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121503
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121505
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121507
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121509
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121511
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121513
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121515
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121517
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121519
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121521
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121523
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121525
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121527
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121529
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121531
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121533
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121535
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121537
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121539
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121541
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121543
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121545
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121547
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121549
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121551
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121553
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121555
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121557
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121559
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121561
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121563
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121565
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121567
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121569
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121571
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121573
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121575
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121577
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121579
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121581
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121583
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121585
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121587
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121589
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121591
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121593
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121595
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121597
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121599
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121601
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121603
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121605
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121607
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121609
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121611
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121613
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121615
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121617
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121619
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121621
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121623
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121625
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121627
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121629
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121631
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121633
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121635
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121637
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121639
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121641
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121643
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121645
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121647
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121649
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121651
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121653
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121655
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121657
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121659
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121661
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121663
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121665
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121667
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121669
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121671
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121673
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121675
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121677
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121679
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121681
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121683
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121685
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121687
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121689
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121691
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121693
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121695
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121697
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121699
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121701
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121703
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121705
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121707
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121709
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121711
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121713
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121715
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121717
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121719
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121721
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121723
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121725
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121727
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121729
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121731
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121733
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121735
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121737
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121739
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121741
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121743
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121745
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121747
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121749
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121751
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121753
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121755
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121757
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121759
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121761
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121763
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121765
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121767
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121769
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121771
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121773
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121775
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121777
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121779
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121781
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121783
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121785
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121787
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121789
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121791
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121793
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121795
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121797
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121799
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121801
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121803
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121805
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121807
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121809
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121811
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121813
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121815
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121817
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121819
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121821
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121823
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121825
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121827
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121829
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121831
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121833
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121835
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121837
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121839
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121841
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121843
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121845
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121847
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121849
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121851
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121853
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121855
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121857
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121859
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121861
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121863
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121865
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121867
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121869
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121871
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121873
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121875
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121877
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121879
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121881
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121883
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121885
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121887
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121889
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121891
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121893
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121895
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121897
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121899
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121901
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121903
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121905
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121907
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121909
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121911
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121913
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121915
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121917
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121919
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121921
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121923
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121925
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121927
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121929
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121931
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121933
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121935
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121937
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121939
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121941
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121943
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121945
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121947
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121949
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121951
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121953
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121955
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121957
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121961
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121963
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121965
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121967
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121969
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121971
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121973
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121975
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121977
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121979
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121981
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121983
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121985
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121987
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121989
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121991
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121993
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121995
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121997
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963121999
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122001
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122003
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122005
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122007
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122009
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122011
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122013
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122015
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122017
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122019
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122021
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122023
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122025
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122027
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122029
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122031
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122033
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122035
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122037
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122039
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122041
Principal investigator 1 ModernaTX, Inc. $957.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122143
Principal investigator 1 ModernaTX, Inc. $957.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122145
Principal investigator 1 ModernaTX, Inc. $957.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122147
Principal investigator 1 ModernaTX, Inc. $957.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122149
Principal investigator 1 ModernaTX, Inc. $957.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122151
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122217
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122219
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122221
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122569
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122571
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122573
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122575
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122577
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122579
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122581
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122583
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122585
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122587
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122589
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122591
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122679
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122849
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122851
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122853
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122855
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122857
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122859
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122861
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122863
Principal investigator 1 ModernaTX, Inc. $67.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963122865
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123107
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123109
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123111
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123113
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123115
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123117
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123119
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123121
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123123
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123125
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123127
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123129
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123131
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123133
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123135
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123137
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123139
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123141
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123143
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123145
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123147
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123149
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123151
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123153
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123155
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123157
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123159
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123161
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123163
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123165
Principal investigator 1 ModernaTX, Inc. $470.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123167
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123217
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123219
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123221
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123223
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123225
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123227
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123229
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123231
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123233
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123235
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123237
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123239
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123241
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123243
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123245
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123247
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123249
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123251
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123253
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123255
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123257
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123259
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123261
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123263
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123265
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123267
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123269
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123271
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123273
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123275
Principal investigator 1 ModernaTX, Inc. $100.00 10/06/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963123277
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906461
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906467
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906473
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906479
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906485
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906489
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906495
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906501
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906507
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906511
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906517
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906523
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906529
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906535
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906539
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906545
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906551
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906557
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906563
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906569
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906573
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906579
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906585
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906591
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906597
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906601
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906607
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906613
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906619
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906625
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906629
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906635
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906641
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906647
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906653
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906659
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906663
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906669
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906675
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906681
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906687
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906691
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906697
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906703
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906709
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906713
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906719
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906725
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906731
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906737
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906743
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906747
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906753
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906759
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906765
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906771
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906777
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906783
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906787
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906793
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906799
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906803
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906809
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906815
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906821
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906827
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906833
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906839
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906845
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906849
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906855
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906861
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906867
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906873
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906881
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906885
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906891
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906897
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906903
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906909
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906915
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906921
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906925
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906931
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906937
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906945
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906949
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906955
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906961
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906965
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906971
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906975
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906981
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906985
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906993
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962906999
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907005
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907009
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907015
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907021
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907027
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907033
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907037
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907043
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907049
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907053
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907059
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907065
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907069
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907075
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907081
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907087
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907093
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907099
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907105
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907111
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907115
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907121
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907127
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907133
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907139
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907145
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907149
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907155
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907161
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907167
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907173
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907179
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907185
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907189
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907195
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907201
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907207
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907211
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907217
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907223
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907229
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907235
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907239
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907245
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907251
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907257
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907263
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907269
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907275
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907279
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907285
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907291
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907297
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907303
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907309
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907313
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907319
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907325
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907331
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907337
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907343
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907349
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907354
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907359
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907365
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907371
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907377
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907382
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907387
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907393
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907399
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907403
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907409
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907415
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907421
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907427
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907433
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907439
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907445
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907449
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907455
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907461
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907467
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907471
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907477
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907483
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907489
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907493
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907499
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907505
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907511
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907515
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907521
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907527
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907533
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907537
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907543
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907549
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907555
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907559
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907565
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907571
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907575
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907581
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907587
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907593
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907599
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907603
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907609
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907615
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907621
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907627
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907633
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907639
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907643
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907649
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907655
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907661
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907665
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907671
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907677
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907683
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907689
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907693
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907699
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907705
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907711
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907717
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907722
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907727
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907733
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907739
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907747
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907751
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907757
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907763
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907769
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907775
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907779
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907785
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907791
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907797
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907803
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907809
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907813
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907819
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907825
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907831
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907836
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907841
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907847
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907853
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907859
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907863
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907869
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907875
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907881
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907887
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907893
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907897
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907903
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907909
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907915
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907919
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907925
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907931
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907937
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907943
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907949
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907955
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907961
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907967
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907971
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907977
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907983
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907989
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962907995
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908001
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908005
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908011
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908017
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908021
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908027
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908033
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908038
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908043
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908049
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908055
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908061
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908067
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908071
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908077
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908083
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908089
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908095
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908101
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908107
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908113
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908117
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908123
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908129
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908135
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908139
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908145
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908151
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908157
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908163
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908169
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908173
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908179
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908185
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908191
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908197
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908201
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908207
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908213
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908219
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908225
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908229
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908235
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908241
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908247
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908253
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908259
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908265
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908271
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908277
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908281
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908287
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908293
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908299
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908305
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908309
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908315
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908321
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908327
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908331
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908337
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908343
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908349
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908353
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908359
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908365
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908371
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908377
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908383
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908387
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908393
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908399
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908405
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908411
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908415
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908421
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908427
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908433
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908439
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908445
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908449
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908455
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908461
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908467
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908471
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908477
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908483
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908489
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908495
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908501
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908507
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908511
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908517
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908523
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908529
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908535
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908540
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908545
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908551
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908557
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908561
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908567
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908573
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908579
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908585
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908589
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908595
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908601
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908607
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908612
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908617
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908623
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908629
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908635
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908639
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908645
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908651
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908657
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908663
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908667
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908673
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908679
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908683
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908689
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908695
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908701
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908707
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908711
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908717
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908723
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908729
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908735
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908739
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908745
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908751
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908757
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908761
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908767
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908773
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908779
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908785
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908791
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908797
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908801
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908807
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908813
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908819
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908825
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908831
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908835
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908841
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908847
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908853
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908857
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908863
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908869
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908875
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908881
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908885
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908891
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908897
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908903
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908909
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908915
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908921
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908925
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908931
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908937
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908943
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908949
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908955
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908961
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908967
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908971
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908977
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908983
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908989
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908995
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962908999
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909005
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909011
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909017
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909023
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909029
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909033
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909039
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909045
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909051
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909057
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909061
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909067
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909073
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909079
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909083
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909091
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909095
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909101
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909107
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909113
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909119
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909125
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909129
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909135
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909141
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909147
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909151
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909157
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909163
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909169
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909175
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909181
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909186
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909191
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909197
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909203
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909209
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909215
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909219
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909225
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909231
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909237
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909243
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909247
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909253
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909259
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909265
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909269
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909275
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909281
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909287
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909293
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909299
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909305
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909311
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909315
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909321
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909327
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909333
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909337
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909343
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909349
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909355
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909359
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909365
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909371
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909377
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909383
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909389
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909393
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909399
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909405
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909411
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909417
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909423
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909427
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909433
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909439
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909445
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909451
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909457
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909461
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909467
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909473
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909479
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909485
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909491
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909495
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909501
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909507
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909511
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909517
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909523
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909529
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909535
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909541
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909547
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909551
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909557
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909563
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909569
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909575
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909579
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909587
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909591
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909597
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909603
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909607
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909613
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909619
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909625
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909631
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909636
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909641
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909647
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909653
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909659
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909665
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909669
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909675
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909681
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909687
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909693
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909699
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909705
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909711
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909715
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909721
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909727
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909733
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909737
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909743
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909749
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909755
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909759
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909765
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909771
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909777
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909781
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909787
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909793
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909799
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909803
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909809
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909815
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909821
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909827
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909831
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909837
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909843
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909849
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909855
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909861
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909865
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909871
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909877
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909881
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909887
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909893
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909897
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909903
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909909
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909915
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909919
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909925
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909931
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909937
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909943
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909948
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909953
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909959
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909965
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909971
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909977
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909982
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909987
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909993
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962909999
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910003
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910009
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910015
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910021
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910027
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910031
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910037
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910043
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910049
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910055
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910059
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910065
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910071
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910077
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910083
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910089
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910095
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910101
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910107
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910113
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910117
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910123
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910129
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910135
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910141
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910147
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910153
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910159
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910165
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910169
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910175
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910181
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910187
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910191
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910197
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910203
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910209
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910215
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910219
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910225
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910231
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910237
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910241
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910247
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910253
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910259
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910265
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910271
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910277
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910283
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910289
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910295
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910301
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910307
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910313
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910319
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910325
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910329
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910335
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910341
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910347
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910351
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910357
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910363
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910369
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910375
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910381
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910387
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910391
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910397
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910403
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910409
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910415
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910421
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910427
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910431
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910437
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910443
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910449
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910455
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910461
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910467
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910473
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910479
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910485
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910491
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910497
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910501
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910507
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910513
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910517
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910523
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910529
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910535
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910541
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910545
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910551
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910557
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910561
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910567
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910573
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910579
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910585
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910589
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910595
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910601
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910607
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910613
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910617
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910623
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910629
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910635
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910641
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910645
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910651
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910657
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910663
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910669
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910673
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910679
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910685
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910691
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910697
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910703
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910707
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910713
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910719
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910725
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910731
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910735
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910741
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910747
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910753
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910759
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910765
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910769
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910775
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910781
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910787
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910793
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910797
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910803
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910809
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910815
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910820
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910826
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910831
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910837
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910843
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910849
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910855
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910859
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910865
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910871
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910877
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910883
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910889
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910893
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910899
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910905
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910911
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910917
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910921
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910927
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910933
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910939
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910943
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910949
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910955
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910961
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910965
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910971
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910977
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910981
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910987
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910993
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962910999
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911005
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911011
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911015
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911021
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911027
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911033
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911037
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911043
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911049
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911053
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911059
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911065
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911070
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911075
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911081
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911087
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911289
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962911295
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912143
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912149
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912155
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912161
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912167
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912173
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912177
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912183
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912189
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912195
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912201
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912207
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912211
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912217
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912223
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912369
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912375
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912741
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912747
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912753
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912757
Principal investigator 1 ModernaTX, Inc. $67.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962912763
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021523
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021529
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021535
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021541
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021547
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021553
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021559
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021565
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021569
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021575
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021581
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021585
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021591
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021597
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021603
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021609
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021613
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021619
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021625
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021631
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021636
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021641
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021647
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021653
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021657
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021663
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021669
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021673
Principal investigator 1 ModernaTX, Inc. $100.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963021679
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057889
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057895
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057899
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057905
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057911
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057917
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057921
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057927
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057933
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057937
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057943
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057949
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057955
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057961
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057965
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057971
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057977
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057981
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057987
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057993
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963057999
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058003
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058009
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058015
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058021
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058026
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058031
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058037
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058043
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058047
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058053
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058059
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058063
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058069
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058075
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058081
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058087
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058091
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058097
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058103
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058109
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058113
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058119
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058125
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058131
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058137
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058143
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058149
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058153
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058159
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058165
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058169
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058175
Principal investigator 1 ModernaTX, Inc. $163.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963058181
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095561
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095565
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095571
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095577
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095583
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095587
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095593
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095599
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095605
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095611
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095617
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095621
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095627
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095633
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095639
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095645
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095649
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095655
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095661
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095667
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095673
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095679
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095683
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095689
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095695
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095701
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095707
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095711
Principal investigator 1 ModernaTX, Inc. $470.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963095717
Principal investigator 1 ModernaTX, Inc. $957.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106153
Principal investigator 1 ModernaTX, Inc. $957.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106155
Principal investigator 1 ModernaTX, Inc. $957.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106157
Principal investigator 1 ModernaTX, Inc. $957.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106159
Principal investigator 1 ModernaTX, Inc. $957.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106161
Principal investigator 1 ModernaTX, Inc. $957.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106163
Principal investigator 1 ModernaTX, Inc. $957.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106165
Principal investigator 1 ModernaTX, Inc. $957.00 08/25/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106167
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927797
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927807
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927815
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927825
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927835
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927845
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927855
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927865
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927873
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927883
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927893
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927903
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927911
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927921
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927931
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927941
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927947
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927957
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927967
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927977
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927987
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962927993
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928003
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928013
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928023
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928033
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928039
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928049
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928059
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928069
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928079
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928087
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928097
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928105
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928115
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928125
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928135
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928141
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928151
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928161
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928171
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928179
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928189
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928199
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928209
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928219
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928229
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928237
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928247
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928255
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928265
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928273
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928281
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928291
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928301
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928311
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928320
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928327
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928333
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928343
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928349
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928359
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928369
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928379
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928387
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928397
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928405
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928415
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928425
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928435
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928441
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928451
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928461
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928467
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928477
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928487
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928497
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928507
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928517
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928527
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928537
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928545
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928553
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928563
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928573
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928583
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928593
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928600
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928609
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928619
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928629
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928639
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928647
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928656
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928665
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928675
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928683
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928693
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928703
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928713
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928723
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928729
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928739
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928749
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928759
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928767
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928776
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928785
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928795
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928805
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928815
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928823
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928833
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928843
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928853
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928863
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928873
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928881
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928891
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928901
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928909
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928917
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928927
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928937
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928945
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928955
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928963
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928973
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928983
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962928993
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929001
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929009
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929019
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929027
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929037
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929047
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929056
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929065
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929073
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929083
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929093
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929101
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929111
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929121
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929131
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929139
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929149
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929157
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929167
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929177
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929187
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929193
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929203
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929213
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929221
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929231
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929241
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929251
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929261
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929269
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929277
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929287
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929297
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929307
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929317
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929323
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929333
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929343
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929353
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929363
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929373
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929383
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929391
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929401
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929411
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929421
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929431
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929441
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929451
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929457
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929467
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929475
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929483
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929493
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929503
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929513
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929521
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929531
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929541
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929551
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929559
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929569
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929579
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929587
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929597
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929607
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929617
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929627
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929635
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929645
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929653
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929661
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929671
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929681
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929689
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929697
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929707
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929717
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929727
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929737
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929747
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929755
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929763
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929773
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929783
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929793
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929803
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929811
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929821
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929829
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929839
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929849
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929859
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929869
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929877
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929887
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929897
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929905
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929915
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929925
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929933
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929941
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929951
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929961
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929971
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929977
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929987
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962929999
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930007
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930017
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930027
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930037
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930045
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930055
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930063
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930073
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930081
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930091
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930100
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930108
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930117
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930127
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930137
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930147
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930155
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930165
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930175
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930183
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930191
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930201
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930211
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930221
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930231
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930239
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930249
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930257
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930267
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930277
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930285
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930295
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930304
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930313
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930323
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930333
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930339
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930349
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930359
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930369
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930379
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930385
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930395
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930405
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930415
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930421
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930431
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930441
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930451
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930459
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930467
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930477
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930487
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930497
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930507
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930515
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930523
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930533
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930543
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930553
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930560
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930569
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930579
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930589
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930599
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930605
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930615
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930625
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930635
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930643
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930651
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930661
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930671
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930679
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930689
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930697
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930707
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930717
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930727
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930737
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930743
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930753
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930763
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930773
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930779
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930789
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930799
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930809
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930817
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930827
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930837
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930845
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930855
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930865
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930873
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930881
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930891
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930901
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930911
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930921
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930931
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930940
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930947
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930957
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930967
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930973
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930983
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962930993
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931001
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931009
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931019
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931029
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931037
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931047
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931057
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931067
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931075
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931085
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931095
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931103
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931113
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931123
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931131
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931141
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931149
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931159
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931169
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931179
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931187
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931197
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931207
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931217
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931227
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931235
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931245
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931254
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931263
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931273
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931283
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931291
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931301
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931309
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931319
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931329
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931339
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931349
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931357
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931365
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931375
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931385
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931395
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931405
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931415
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931423
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931433
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931443
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931453
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931463
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931471
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931481
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931491
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931501
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931509
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931519
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931527
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931537
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931547
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931557
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931565
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931575
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931585
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931593
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931605
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931613
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931621
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931631
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931639
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931647
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931657
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931667
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931678
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931685
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931695
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931705
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931715
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931725
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931731
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931741
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931751
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931757
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931767
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931777
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931787
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931797
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931805
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931815
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931823
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931833
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931843
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931851
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931861
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931869
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931879
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931889
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931899
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931907
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931917
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931927
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931937
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931945
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931953
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931963
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931973
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931983
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962931993
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962932001
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962932009
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962932019
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962932029
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962932039
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962932047
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962932559
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962932569
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962932579
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962934999
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935009
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935019
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935029
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935035
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935045
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935055
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935065
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935073
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935083
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935091
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935103
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935113
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962935575
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962936761
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962936767
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962936777
Principal investigator 1 ModernaTX, Inc. $67.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962936787
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022645
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022651
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022657
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022663
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022667
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022673
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022679
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022683
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022689
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022695
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022701
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022705
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022711
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022717
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022723
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022729
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022733
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022739
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022745
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022751
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022755
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022761
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022767
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022773
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022777
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022783
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022789
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022795
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022801
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022805
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022811
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022817
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022823
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022829
Principal investigator 1 ModernaTX, Inc. $100.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963022835
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096747
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096753
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096759
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096765
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096769
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096775
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096781
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096787
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096793
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096797
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096803
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096809
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096815
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096821
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096827
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096833
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096837
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096843
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096849
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096855
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096861
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096865
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096871
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096877
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096883
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096887
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096893
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096899
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096905
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096911
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096917
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096923
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096929
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096933
Principal investigator 1 ModernaTX, Inc. $470.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963096939
Principal investigator 1 ModernaTX, Inc. $957.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106289
Principal investigator 1 ModernaTX, Inc. $957.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106291
Principal investigator 1 ModernaTX, Inc. $957.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106293
Principal investigator 1 ModernaTX, Inc. $957.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106295
Principal investigator 1 ModernaTX, Inc. $957.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106297
Principal investigator 1 ModernaTX, Inc. $957.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106299
Principal investigator 1 ModernaTX, Inc. $957.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106301
Principal investigator 1 ModernaTX, Inc. $957.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106303
Principal investigator 1 ModernaTX, Inc. $957.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106305
Principal investigator 1 ModernaTX, Inc. $957.00 08/18/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963106307
Principal investigator 1 ModernaTX, Inc. $3,843.00 08/01/2022 Non-covered Recipient Entity
Optimal Research LLC
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 963546935
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769707
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769709
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769711
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769713
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769717
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769719
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769721
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769723
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769725
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769727
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769729
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769731
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769733
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769735
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769737
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769739
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769741
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769743
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769745
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769747
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769749
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769751
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769753
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769755
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769757
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769759
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769763
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769765
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769767
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769769
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769771
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769773
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769775
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769777
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769779
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769781
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769783
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769785
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769787
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769789
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769791
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769793
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769795
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769797
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769799
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769801
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769803
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769805
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769807
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769809
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769811
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769813
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769815
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769817
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769819
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769821
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769823
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769825
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769827
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769829
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769831
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769833
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769835
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769837
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769839
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769841
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769843
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769845
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769847
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769849
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769851
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769853
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769855
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769857
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769859
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769861
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769863
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769865
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769867
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769869
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769871
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769873
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769875
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769877
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769879
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769881
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769883
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769885
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769887
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769889
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769891
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769893
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769895
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769897
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769899
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769901
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769903
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769905
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769907
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769909
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769911
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769913
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769915
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769917
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769919
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769921
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769923
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769925
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769927
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769929
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769931
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769933
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769935
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769937
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769939
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769941
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769943
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769945
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769947
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769949
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769951
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769953
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769955
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769957
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769959
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769961
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769963
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769965
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769967
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769969
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769971
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769973
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769975
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769977
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769979
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769981
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769983
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769985
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769987
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769989
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769991
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769993
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769995
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769997
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962769999
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770001
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770003
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770005
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770007
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770009
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770011
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770013
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770015
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770017
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770019
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770021
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770023
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770025
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770027
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770029
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770031
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770033
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770035
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770037
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770039
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770041
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770043
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770045
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770047
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770049
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770051
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770053
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770055
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770057
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770059
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770061
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770063
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770065
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770067
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770069
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770071
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770073
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770075
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770077
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770079
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770081
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770083
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770085
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770087
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770089
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770091
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770093
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770095
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770097
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770099
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770101
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770103
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770105
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770107
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770109
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770111
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770113
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770115
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770117
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770119
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770121
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770123
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770125
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770127
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770129
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770131
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770133
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770135
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770137
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770139
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770141
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770143
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770145
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770147
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770149
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770151
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770153
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770155
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770157
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770159
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770161
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770163
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770165
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770167
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770169
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770171
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770173
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770175
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770179
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770181
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770183
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770185
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770187
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770189
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770191
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770193
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770195
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770197
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770199
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770201
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770203
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770205
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770207
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770209
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770211
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770213
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770215
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770217
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770219
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770221
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770223
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770225
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770227
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770229
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770231
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770233
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770235
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770237
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770239
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770241
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770243
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770245
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770247
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770249
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770251
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770253
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770255
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770257
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770259
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770261
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770263
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770265
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770267
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770269
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770271
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770273
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770275
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770277
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770279
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770281
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770283
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770285
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770287
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770289
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770291
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770293
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770295
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770297
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770299
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770301
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770303
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770305
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770307
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770309
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770311
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770313
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770315
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770317
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770319
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770321
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770323
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770325
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770327
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770331
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770333
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770335
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770337
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770339
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770341
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770343
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770345
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770347
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770349
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770351
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770353
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962770355
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856865
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856869
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856875
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856881
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856885
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856893
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856899
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856905
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856911
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856915
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856921
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856927
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856933
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856939
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856944
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856949
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856955
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856961
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856967
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856973
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856977
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856983
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856989
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856995
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962856999
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857005
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857011
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857017
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857021
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857027
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857033
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857039
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857045
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857051
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857055
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857061
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857067
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857073
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857077
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857083
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857089
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857095
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857099
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857105
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857111
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857117
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857121
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857127
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857133
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857139
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857145
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857149
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857155
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857161
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857167
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857173
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857179
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857183
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857189
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857195
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857201
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857205
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857211
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857217
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857223
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857229
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857233
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857239
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857245
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857251
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857257
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857261
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857267
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857273
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857279
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857285
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857291
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857297
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857303
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857307
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857313
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857319
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857325
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857331
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857335
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857341
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857347
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857353
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857359
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857363
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857369
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857375
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857381
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857385
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857391
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857397
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857403
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857407
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857413
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857419
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857425
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857431
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857437
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857443
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857447
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857453
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857459
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857465
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857471
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857477
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857481
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857487
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857493
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857499
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857503
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857509
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857515
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857521
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857527
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857533
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857539
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857543
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857549
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857555
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857561
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857567
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857573
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857577
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857583
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857589
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857593
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857599
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857605
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857611
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857617
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857623
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857627
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857633
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857639
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857643
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857649
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857655
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857661
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857665
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857671
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857677
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857683
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857689
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857695
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857699
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857705
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857711
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857717
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857721
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857727
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857733
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857739
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857745
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857751
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857755
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857761
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857767
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857773
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857779
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857783
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857789
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857795
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857801
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857807
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857813
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857817
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857823
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857829
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857835
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857839
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857845
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857851
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857857
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857861
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857867
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857873
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857879
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857883
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857889
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857895
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857899
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857905
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857911
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857917
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857923
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857927
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857933
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857939
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857945
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857951
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857957
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857963
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857969
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857973
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857979
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857985
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857991
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962857997
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858001
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858007
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858013
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858019
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858025
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858031
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858037
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858041
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858047
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858053
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858059
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858065
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858069
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858075
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858081
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858087
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858093
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858097
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858103
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858109
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858115
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858121
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858125
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858131
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858137
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858143
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858149
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858153
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858159
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858165
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858171
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858175
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858181
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858187
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858193
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858199
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858203
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858209
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858215
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858221
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858227
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858231
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858237
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858243
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858249
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858255
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858259
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858265
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858271
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858277
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858283
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858289
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858295
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858299
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858305
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858311
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858317
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858323
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858329
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858333
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858339
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858345
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858351
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858357
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858363
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858367
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858373
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858379
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858385
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858391
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858395
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858401
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858407
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858413
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858417
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858423
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858429
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858434
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858439
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858445
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858451
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858457
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858463
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858467
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858473
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858479
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858485
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858491
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858497
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858503
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858509
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858513
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858519
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858525
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858531
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858537
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858543
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858547
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858553
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858559
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858565
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858571
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858575
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858581
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858587
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858593
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858599
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858605
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858609
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858615
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858621
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858627
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858633
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858637
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858643
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858649
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858655
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858661
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858667
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858673
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858677
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858683
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858689
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858693
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858699
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858705
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858711
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858715
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858721
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858727
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858733
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858740
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858745
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858751
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858757
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858763
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858767
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858773
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858779
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858785
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858791
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858797
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858803
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858807
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858813
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858819
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858825
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858831
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858837
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858841
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858847
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858853
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858858
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858863
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858869
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858875
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858881
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858887
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858891
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858897
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858903
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858909
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858915
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858919
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858925
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858931
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858937
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858941
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858947
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858953
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858957
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858963
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858969
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858975
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858979
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858985
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858991
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962858997
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859003
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859009
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859013
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859019
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859025
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859031
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859037
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859041
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859047
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859053
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859059
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859065
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859069
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859075
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859081
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859087
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859093
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859097
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859103
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859109
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859115
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859119
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859125
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859131
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859137
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859143
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859149
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859155
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859161
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859167
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859173
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859177
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859183
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859189
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859195
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859199
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859205
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859211
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859215
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859221
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859227
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859233
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962859393
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962860021
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962860025
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962860031
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962860037
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962860043
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962860047
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962860053
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962860059
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962860065
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962860149
Principal investigator 1 ModernaTX, Inc. $67.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962860155
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019451
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019457
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019463
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019469
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019475
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019479
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019485
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019491
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019497
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019503
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019509
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019513
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019519
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019525
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019531
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019537
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019541
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019547
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019553
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019559
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019563
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019569
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019575
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019579
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019585
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019591
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019595
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019601
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019607
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019613
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019617
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019623
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019629
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019635
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019639
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019645
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019651
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019659
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963019665
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963051979
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963051985
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963051989
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963051995
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963052001
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963052005
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963052011
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963052017
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963052023
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963052029
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963052033
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963052039
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963052045
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963052051
Principal investigator 1 ModernaTX, Inc. $163.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963052057
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093526
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093531
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093537
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093543
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093547
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093553
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093559
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093563
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093569
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093575
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093581
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093587
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093591
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093597
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093603
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093609
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093615
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093619
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093625
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093631
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093637
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093643
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093647
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093653
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093659
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093663
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093669
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093673
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093679
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093685
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093691
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093695
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093701
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093707
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093711
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093717
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093723
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093728
Principal investigator 1 ModernaTX, Inc. $470.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963093733
Principal investigator 1 ModernaTX, Inc. $957.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963105987
Principal investigator 1 ModernaTX, Inc. $957.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963105989
Principal investigator 1 ModernaTX, Inc. $957.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963105991
Principal investigator 1 ModernaTX, Inc. $957.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963105993
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963109623
Principal investigator 1 ModernaTX, Inc. $25.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963109625
Principal investigator 1 ModernaTX, Inc. $50.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963110783
Principal investigator 1 ModernaTX, Inc. $50.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963110785
Principal investigator 1 ModernaTX, Inc. $50.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963110799
Principal investigator 1 ModernaTX, Inc. $50.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963110801
Principal investigator 1 ModernaTX, Inc. $50.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963110819
Principal investigator 1 ModernaTX, Inc. $50.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963110821
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963111113
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963111115
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963111129
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963111131
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963111149
Principal investigator 1 ModernaTX, Inc. $100.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963111151
Principal investigator 1 ModernaTX, Inc. $211.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963111899
Principal investigator 1 ModernaTX, Inc. $211.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963111901
Principal investigator 1 ModernaTX, Inc. $597.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963113211
Principal investigator 1 ModernaTX, Inc. $597.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963113213
Principal investigator 1 ModernaTX, Inc. $597.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963113227
Principal investigator 1 ModernaTX, Inc. $597.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963113229
Principal investigator 1 ModernaTX, Inc. $597.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963113247
Principal investigator 1 ModernaTX, Inc. $597.00 07/13/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years No dispute reported 06/30/2026 963113249
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764165
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764167
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764169
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764171
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764173
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764175
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764177
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764179
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764181
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764183
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764185
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764187
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764189
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764191
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764193
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764195
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764197
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764199
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764201
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764203
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764205
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764207
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764209
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764211
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764213
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764215
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764217
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764219
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764221
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764223
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764225
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764227
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764229
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764231
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764233
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764235
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764237
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764239
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764241
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764243
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764245
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764247
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764249
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764251
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764253
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764255
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764257
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764259
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764261
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764263
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764265
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764267
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764269
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764271
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764273
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764275
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764277
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764279
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764281
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764283
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764285
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764287
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764289
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764291
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764293
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764295
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764299
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764301
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764303
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764305
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764307
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764309
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764311
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764313
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764315
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764317
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764319
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764321
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764323
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764325
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764327
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764329
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764331
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764333
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764335
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764337
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764339
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764341
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764343
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764345
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764347
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764349
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764351
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764353
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764355
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764357
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764359
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764361
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764363
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764365
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764367
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764369
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764371
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764373
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764375
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764377
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764379
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764381
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764383
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764385
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764387
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764389
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764391
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764393
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764395
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764397
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764399
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764401
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764403
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764405
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764407
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764409
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764411
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764413
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764415
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764417
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764419
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764421
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764423
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764425
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764427
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764429
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764431
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764433
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764435
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764437
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764439
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764441
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764443
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764445
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764447
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764449
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764451
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764453
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764455
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764457
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764459
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764461
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764463
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764465
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764467
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764469
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764471
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764473
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764475
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764477
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764479
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764481
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764483
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764485
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764487
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764489
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764491
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764493
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764495
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764497
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764499
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764501
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764503
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764505
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764507
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764509
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764511
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764513
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764515
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764517
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764519
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764521
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764523
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764525
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764527
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764529
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764531
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764533
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764535
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764537
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764539
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764541
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764543
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764545
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764547
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764549
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764551
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764553
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764555
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764557
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764559
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764561
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764563
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764565
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764567
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764569
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764571
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764573
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764575
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764577
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764579
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764581
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764583
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764585
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764587
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764589
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764591
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764593
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764595
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764597
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764599
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764601
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764603
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764605
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764607
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764609
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764611
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764613
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764615
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764617
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764619
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764621
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764623
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764625
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764627
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764631
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764633
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764635
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764637
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764639
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764641
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764643
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764645
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764647
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764649
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764651
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764653
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764655
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764657
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764659
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764661
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764663
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764665
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764667
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764669
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764671
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764673
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764675
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764677
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764679
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764681
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764683
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764685
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764687
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764689
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764691
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764693
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764695
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764697
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764699
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764701
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764703
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764705
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764707
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764709
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764711
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764713
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764715
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764717
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764719
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764721
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764723
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764725
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764727
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764729
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764731
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764733
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764735
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764737
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764739
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764741
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764743
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764745
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764747
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764749
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764751
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764753
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764755
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764757
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764759
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764761
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764763
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764765
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764767
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764769
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764771
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764773
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764775
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764777
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764779
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764781
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764783
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764785
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764787
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764789
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764791
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764793
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764795
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764797
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764799
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764801
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764803
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764805
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764807
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764809
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764811
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764813
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764815
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764817
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764819
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764821
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764823
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764825
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764827
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764829
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764831
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764833
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764835
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764837
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764839
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764841
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764843
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764845
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764847
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764849
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764851
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764853
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764855
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764857
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764859
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764861
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764863
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764865
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764867
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764869
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764871
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764873
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764875
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764877
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764879
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764881
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764883
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764885
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764887
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764889
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764891
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764893
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764895
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764897
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764899
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764901
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764903
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764905
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764907
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764909
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764911
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764913
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764915
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764917
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764919
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764921
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764923
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764925
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764927
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764929
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764931
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764933
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764935
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764937
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764939
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764941
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764943
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764945
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764947
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764949
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764951
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764953
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764955
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764957
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764959
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764961
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764963
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764965
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764967
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764969
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764971
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764973
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764975
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764977
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764979
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764981
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764983
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764985
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764987
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764989
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764991
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764993
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764995
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764997
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962764999
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765001
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765003
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765005
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765007
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765009
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765011
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765013
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765015
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765017
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765019
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765021
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765023
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765025
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765027
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765029
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765031
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765033
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765035
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765037
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765039
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765041
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765043
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765045
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765047
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765049
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765051
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765053
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765055
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765057
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765059
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765061
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765063
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765065
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765067
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765069
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765071
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765073
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765075
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765077
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765079
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765081
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765083
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765085
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765087
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765089
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765091
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765093
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765095
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765097
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765099
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765101
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765103
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765105
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765107
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765109
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765111
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765113
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765115
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765117
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765119
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765121
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765123
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765125
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765127
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765129
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765131
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765133
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765135
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765137
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765139
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765141
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765143
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765145
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765147
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765149
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765151
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765153
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765155
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765157
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765221
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765223
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765225
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765227
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765229
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765231
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765233
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765235
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765237
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765239
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765241
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765243
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765245
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765247
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765249
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765251
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765253
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765255
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765257
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765259
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765261
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765263
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765265
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765267
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765269
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765271
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765273
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765275
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765277
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765279
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765281
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765283
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765285
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765287
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765289
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765291
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765293
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765295
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765297
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765299
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765301
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765303
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765305
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765307
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765309
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765311
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765313
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765315
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765317
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765319
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765321
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765323
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962765325
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776031
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776033
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776035
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776037
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776039
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776041
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776043
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776045
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776047
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776049
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776051
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776053
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776055
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776057
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776059
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776061
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776063
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776065
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776067
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776069
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776071
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776073
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776075
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776077
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776079
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776081
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776083
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776085
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776087
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776089
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776091
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776093
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776095
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776097
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776099
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776101
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776103
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776105
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776107
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776109
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776111
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776113
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776115
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776117
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776119
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776121
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776123
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776125
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776127
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776129
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776131
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776133
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776135
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776137
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776139
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776141
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776143
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776145
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776147
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776149
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776151
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776153
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776155
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776157
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776159
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776161
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776163
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776165
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776167
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776169
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776171
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776173
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776175
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776177
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776179
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776181
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776183
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776185
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776187
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776189
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776191
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776193
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776195
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776197
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776199
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776201
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776203
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776205
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776207
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776209
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776211
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776213
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776215
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776217
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776219
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776221
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776223
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776225
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776227
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776229
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776231
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776233
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776235
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776237
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776239
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776241
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776243
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776245
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776247
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776249
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776251
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776253
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776255
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776257
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776259
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776261
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776263
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776265
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776267
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776269
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776271
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776273
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776275
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776277
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776279
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776281
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776283
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776285
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776287
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776289
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776291
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776293
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776295
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776297
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776299
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776301
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776303
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776305
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776307
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776309
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776311
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776313
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776315
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776317
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776319
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776321
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776323
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776325
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776327
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776329
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776331
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776333
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776335
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776337
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776339
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776341
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776343
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776345
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776347
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776349
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776351
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776353
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776355
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776357
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776359
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776361
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776363
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776365
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776367
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776369
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776371
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776373
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776375
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776377
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776379
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776381
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776383
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776385
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776387
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776389
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776391
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776393
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776395
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776397
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776399
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776401
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776403
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776405
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776407
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776409
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776411
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776413
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776415
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776417
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776419
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776421
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776423
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776425
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776427
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776429
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776431
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776433
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776435
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776437
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776439
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776441
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776443
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776445
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776447
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776449
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776451
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776453
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776455
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776457
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776459
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776461
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776463
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776465
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776467
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776469
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776471
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776473
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776475
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776477
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776479
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776481
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776483
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776485
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776487
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776489
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776491
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776493
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776495
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776497
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776499
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776501
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776503
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776505
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776507
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776509
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776511
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776513
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776515
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776517
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776519
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776521
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776523
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776525
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776527
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776529
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776531
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776533
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776535
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776537
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776539
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776541
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776543
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776545
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776547
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776549
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776551
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776553
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776555
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776557
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776559
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776561
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776563
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776565
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776567
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776569
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776571
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776573
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776575
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776577
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776579
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776581
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776583
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776585
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776587
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776589
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776591
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776593
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776595
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776597
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776599
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776601
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776603
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776605
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776607
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776609
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776611
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776613
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776615
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776617
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776619
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776621
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776623
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776625
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776627
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776629
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776631
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776633
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776635
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776637
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776639
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776641
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776643
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776645
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776647
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776649
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776651
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776653
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776655
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776657
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776659
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776661
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776663
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776665
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776667
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776669
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776671
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776673
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776675
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776677
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776679
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776681
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776683
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776685
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776687
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776689
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776691
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776693
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776695
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776697
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776699
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776701
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776703
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776705
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776707
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776709
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776711
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776713
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776715
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776717
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776719
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776721
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776723
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776725
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776727
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776729
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776731
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776733
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776735
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776737
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776739
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776741
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776743
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776745
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776747
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776749
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776751
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776753
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776755
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776757
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776759
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776761
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776763
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776765
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776767
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776769
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776771
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776773
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776775
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776777
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776779
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776781
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776783
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776785
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776787
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776789
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776791
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776793
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776795
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776797
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776799
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776801
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776803
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776805
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776807
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776809
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776811
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776813
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776815
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776817
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776819
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776821
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776823
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776825
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776827
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776829
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776831
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776833
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776835
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776837
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776839
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776841
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776843
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776845
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776847
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776849
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776851
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776853
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776855
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776857
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776859
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776861
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776863
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776865
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776867
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776869
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776871
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776873
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776875
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776877
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776879
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776881
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776883
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776885
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776887
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776889
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776891
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776893
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776895
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776897
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776899
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776901
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776903
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776905
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776907
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776909
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776911
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776913
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776915
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776917
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776919
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776921
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776923
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776925
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776927
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776929
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776931
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776933
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776935
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776937
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776939
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776941
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776943
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776945
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776947
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776949
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776951
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776953
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776955
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776957
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776959
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776961
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776963
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776965
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776967
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776969
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776971
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776973
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776975
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776977
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776979
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776981
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776983
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776985
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776987
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776989
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776991
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776993
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776995
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776997
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962776999
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777001
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777003
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777005
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777007
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777009
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777011
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777013
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777015
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777017
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777019
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777021
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777023
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777025
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777027
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777029
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777031
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777033
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777035
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777037
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777039
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777041
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777043
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777045
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777047
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777049
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777051
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777053
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777055
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777057
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777059
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777061
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777063
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777065
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777067
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777069
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777071
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777073
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777075
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777077
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777079
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777081
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777083
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777085
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777087
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777089
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777091
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777093
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777095
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777097
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777099
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777101
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777103
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777105
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777107
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777109
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777111
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777113
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777115
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777117
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777119
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777121
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777123
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777125
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777127
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777129
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777131
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777133
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777135
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777137
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777139
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777141
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777143
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777145
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777147
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777149
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777151
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777153
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777155
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777157
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777159
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777161
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777163
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777165
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777167
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777169
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777171
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777173
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777175
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777177
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777179
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777181
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777183
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777185
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777187
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777189
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777191
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777193
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777195
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777197
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777199
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777201
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777203
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777205
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777207
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777209
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777211
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777213
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777215
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777217
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777219
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777221
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777223
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777225
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777227
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777229
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777231
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777233
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777235
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777237
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777239
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777241
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777243
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777245
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777247
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777249
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777251
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777253
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777255
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777257
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777259
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777261
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777263
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777265
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777267
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777269
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777271
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777273
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777275
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777277
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777279
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777281
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777283
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777285
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777287
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777289
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777291
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777295
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777297
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777299
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777301
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777303
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777305
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777307
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777309
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777311
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777313
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777315
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777317
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777319
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777321
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777323
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777325
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777327
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777329
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777331
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777333
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777335
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777337
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777339
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777341
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777343
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777345
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777347
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777349
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777351
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777353
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777355
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777357
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777359
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777361
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777363
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777365
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777367
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777369
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777371
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777373
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777375
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777377
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777379
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777381
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777383
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777385
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777387
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777389
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777391
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777393
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777395
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777397
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777399
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777401
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777403
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777405
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777407
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777409
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777411
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777413
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777415
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777417
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777419
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777421
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777423
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777425
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777427
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777429
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777431
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777433
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777437
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777449
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777451
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777453
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962777455
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782805
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782807
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782809
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782811
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782813
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782815
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782817
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782819
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782821
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782823
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782825
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782827
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782829
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782831
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782833
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782835
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782837
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782839
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782841
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782843
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782845
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782847
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782849
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782851
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782853
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782855
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782857
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782859
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782861
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782863
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782865
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782867
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782869
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782871
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782873
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782875
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782877
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782879
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782881
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782883
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782885
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782887
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782889
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782891
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782893
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782895
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782897
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782899
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782901
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782903
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782905
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782907
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782909
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782911
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782913
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782915
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782917
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782919
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782921
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782923
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782925
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782927
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782929
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782931
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782933
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782935
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782937
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782939
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782941
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782943
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782945
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782947
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782949
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782951
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782953
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782955
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782957
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782959
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782961
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782963
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782965
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782967
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782969
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782971
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782973
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782975
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782977
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782979
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782981
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782983
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782985
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782987
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782989
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782991
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782993
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782995
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782997
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962782999
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783001
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783003
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783005
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783007
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783009
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783011
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783013
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783015
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783017
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783019
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783021
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783023
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783025
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783027
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783029
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783031
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783035
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783037
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783039
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783041
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783043
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783045
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783047
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783049
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783051
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783053
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783055
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783057
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783059
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783061
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783063
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783065
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783067
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783069
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783071
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783073
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783075
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783077
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783079
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783081
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783083
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783085
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783087
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783089
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783091
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783093
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783095
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783097
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783099
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783101
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783103
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783105
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783107
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783109
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783111
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783115
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783117
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783119
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783121
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783123
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783125
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783127
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783129
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783131
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783133
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783135
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783137
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783139
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783141
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783143
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783145
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783147
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783149
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783151
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783153
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783155
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783157
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783159
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783161
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783163
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783165
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783167
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783169
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783171
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783173
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783175
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783177
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783179
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783181
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783183
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783185
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783187
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783189
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783191
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783193
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783195
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783197
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783199
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783201
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783203
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783205
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783207
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783209
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783211
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783213
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783215
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783217
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783219
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783223
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783225
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783227
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783229
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783231
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783233
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783235
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783237
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783239
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783241
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783243
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783245
Principal investigator 1 ModernaTX, Inc. $25.00 07/08/2022 Non-covered Recipient Entity
Synexus Clinical Research Limited
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 962783247